Regeneron Pharmaceuticals Highlights Progress Across Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
Monday, 9 September 2024, 04:06
Oncology Portfolio Highlights
Regeneron Pharmaceuticals, a leader in oncology advancements, is set to showcase its progress at WCLC and ESMO. This will include significant findings from their differentiated oncology portfolio.
WCLC Presentation
- Five-Year Survival Data: This data will focus on Libtayo, a PD-1 inhibitor, used as first-line monotherapy in advanced non-small cell lung cancer.
ESMO Insights
- Investigational Fianlimab: Regeneron will present longer-term results, highlighting its potential in oncology.
Regeneron's continuous commitment to innovation in oncology is evident through these presentations, reflecting its strategic initiatives in the medical landscape.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.